Outlook Therapeutics Inc (OTLK)
7.29
-0.22
(-2.93%)
USD |
NASDAQ |
Jun 28, 16:00
7.29
0.00 (0.00%)
After-Hours: 20:00
Outlook Therapeutics Research and Development Expense (TTM): 34.08M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 34.08M |
| December 31, 2023 | 21.12M |
| September 30, 2023 | 26.45M |
| June 30, 2023 | 30.50M |
| March 31, 2023 | 30.65M |
| December 31, 2022 | 42.32M |
| September 30, 2022 | 42.33M |
| June 30, 2022 | 43.28M |
| March 31, 2022 | 40.57M |
| December 31, 2021 | 36.88M |
| September 30, 2021 | 38.96M |
| June 30, 2021 | 36.65M |
| March 31, 2021 | 36.59M |
| December 31, 2020 | 32.44M |
| September 30, 2020 | 26.34M |
| June 30, 2020 | 26.17M |
| March 31, 2020 | 22.03M |
| December 31, 2019 | 23.58M |
| Date | Value |
|---|---|
| September 30, 2019 | 23.81M |
| June 30, 2019 | 23.50M |
| March 31, 2019 | 24.95M |
| December 31, 2018 | 24.17M |
| September 30, 2018 | 18.50M |
| June 30, 2018 | 13.66M |
| March 31, 2018 | 12.02M |
| December 31, 2017 | 10.98M |
| September 30, 2017 | 23.81M |
| June 30, 2017 | 25.38M |
| March 31, 2017 | 33.24M |
| December 31, 2016 | 33.26M |
| September 30, 2016 | 32.76M |
| June 30, 2016 | 42.09M |
| March 31, 2016 | 39.75M |
| December 31, 2015 | 45.77M |
| September 30, 2015 | 38.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
21.12M
Minimum
Dec 2023
43.28M
Maximum
Jun 2022
31.91M
Average
31.54M
Median
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 9.851B |
| Orthofix Medical Inc | 76.42M |
| Actinium Pharmaceuticals Inc | 37.46M |
| Marinus Pharmaceuticals Inc | 95.57M |
| Recursion Pharmaceuticals Inc | 262.11M |